DE69421366T2 - Staurosporinderivate und Polyalkylenglykol-Glyceride enthaltende Arzneimittel - Google Patents

Staurosporinderivate und Polyalkylenglykol-Glyceride enthaltende Arzneimittel

Info

Publication number
DE69421366T2
DE69421366T2 DE69421366T DE69421366T DE69421366T2 DE 69421366 T2 DE69421366 T2 DE 69421366T2 DE 69421366 T DE69421366 T DE 69421366T DE 69421366 T DE69421366 T DE 69421366T DE 69421366 T2 DE69421366 T2 DE 69421366T2
Authority
DE
Germany
Prior art keywords
polyalkylene glycol
medicines containing
staurosporine derivatives
glycol glycerides
containing staurosporine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69421366T
Other languages
English (en)
Other versions
DE69421366D1 (de
Inventor
Roy Lindsay Allen Henry
Graham Paul Matthews
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE69421366D1 publication Critical patent/DE69421366D1/de
Publication of DE69421366T2 publication Critical patent/DE69421366T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE69421366T 1993-12-11 1994-12-02 Staurosporinderivate und Polyalkylenglykol-Glyceride enthaltende Arzneimittel Expired - Lifetime DE69421366T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939325395A GB9325395D0 (en) 1993-12-11 1993-12-11 Compositions

Publications (2)

Publication Number Publication Date
DE69421366D1 DE69421366D1 (de) 1999-12-02
DE69421366T2 true DE69421366T2 (de) 2000-03-23

Family

ID=10746475

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69421366T Expired - Lifetime DE69421366T2 (de) 1993-12-11 1994-12-02 Staurosporinderivate und Polyalkylenglykol-Glyceride enthaltende Arzneimittel

Country Status (17)

Country Link
US (1) US5736542A (de)
EP (1) EP0657164B1 (de)
JP (1) JPH07196512A (de)
KR (1) KR100366176B1 (de)
AT (1) ATE185970T1 (de)
AU (1) AU692801B2 (de)
CA (1) CA2137764C (de)
DE (1) DE69421366T2 (de)
DK (1) DK0657164T3 (de)
ES (1) ES2140512T3 (de)
GB (1) GB9325395D0 (de)
GR (1) GR3032368T3 (de)
IL (1) IL111872A (de)
NZ (1) NZ270109A (de)
PH (1) PH31454A (de)
PT (1) PT657164E (de)
ZA (1) ZA949824B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
EP1201668A4 (de) 1999-07-13 2003-05-21 Kyowa Hakko Kogyo Kk Staurosporin-derivate
DE10042137A1 (de) * 2000-08-28 2002-03-14 Florian Lang sgk2 und sgk3 als diagnostische und therapeutische Targets
CN100350911C (zh) * 2001-03-26 2007-11-28 诺瓦提斯公司 含有水溶性差的活性成分、表面活性剂和水溶性聚合物的药物组合物
BR0318166A (pt) * 2003-03-03 2006-04-04 Florian Lang uso de uma substáncia para detectar sgk1, kit para essa detecção, bem como composição farmacêutica que inibe ou ativa a sua expressão e/ou função
US20040246627A1 (en) * 2003-06-06 2004-12-09 Durrum Thomas M. Disc drive pivot bearing assembly
BRPI0413439A (pt) 2003-08-08 2006-10-17 Novartis Ag combinações compreendendo estaurosporinas
PL1660047T3 (pl) 2003-08-13 2014-05-30 Biocon Ltd Formulacje dawek stałych mikrocząsteczek soli kwasów tłuszczowych do środków terapeutycznych
WO2006082448A1 (en) * 2005-02-07 2006-08-10 Topotarget Uk Limited Assays for agents with selective cytotoxicty to hdac resistant cell lines
US9994585B2 (en) * 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US20100168219A1 (en) * 2008-12-31 2010-07-01 Jonathan Steven Alexander Chronic inflammation and transplantation
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
US10828276B2 (en) 2012-11-28 2020-11-10 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60185719A (ja) * 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
JPH0699311B2 (ja) * 1986-11-06 1994-12-07 旭化成工業株式会社 抗血管レン縮剤および血管弛緩剤
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
JPH01143877A (ja) * 1987-11-30 1989-06-06 Asahi Chem Ind Co Ltd スタウロスポリン誘導体
WO1989007105A1 (en) * 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
CA2107218A1 (en) * 1991-03-29 1992-09-30 Stuart H. Yuspa Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors
JPH0597708A (ja) * 1991-10-02 1993-04-20 Lion Corp 歯周病治療剤
AU2866992A (en) * 1991-10-10 1993-05-03 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤

Also Published As

Publication number Publication date
GB9325395D0 (en) 1994-02-16
NZ270109A (en) 1996-11-26
ZA949824B (en) 1995-07-13
PH31454A (en) 1998-11-03
CA2137764A1 (en) 1995-06-12
US5736542A (en) 1998-04-07
IL111872A0 (en) 1995-06-29
ES2140512T3 (es) 2000-03-01
KR960021018A (ko) 1996-07-18
DK0657164T3 (da) 2000-04-17
JPH07196512A (ja) 1995-08-01
AU692801B2 (en) 1998-06-18
EP0657164A1 (de) 1995-06-14
KR100366176B1 (ko) 2003-03-03
PT657164E (pt) 2000-04-28
ATE185970T1 (de) 1999-11-15
CA2137764C (en) 2006-02-07
EP0657164B1 (de) 1999-10-27
AU8030894A (en) 1995-06-22
DE69421366D1 (de) 1999-12-02
GR3032368T3 (en) 2000-04-27
IL111872A (en) 1998-02-08

Similar Documents

Publication Publication Date Title
DE69421366D1 (de) Staurosporinderivate und Polyalkylenglykol-Glyceride enthaltende Arzneimittel
PT750495E (pt) Utilizacao de um surfactante lipofilico numa composicao farmaceutica
DE69506642D1 (de) Pharmazeutische Zubereitungen enthaltend mehrfach ungesättigte Fettsäuren zusammen mit antioxydativen Vitaminen und Provitaminen
SE8004938L (sv) Farmaceutisk kompositon av fast lekemedel med fordrojd frigoring
DE3780222T2 (de) Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung.
ATE374602T1 (de) Orale kapselformulierung mit verbesserter physikalischer stabilität
ATE153854T1 (de) Stabile pharmazeutische zubereitung mit fumagillolderivaten
ES2101574T3 (es) Composicion administrable por via oral apta para formar una microemulsion.
DE60205633D1 (de) Orale pharmazeutische zusammensetzung mit einem wirkstoff, der bei seiner ersten darmpassage starken wirkungen ausgesetzt werden kann
KR950010875A (ko) 피부외용제
RS49602B (sr) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
ATE117200T1 (de) Probucol enthaltendes arzneimittel mit gesteigerter bioverfügbarkeit.
BE1002024A6 (fr) Preparation medicamenteuse a base de derives d'esters d'hecogenine et leur utilisation pour le traitement de l'hyperplasie prostatique benigne.
WO1999008666A3 (en) Pharmaceutical composition comprising an azateroid
SE8600496D0 (sv) Pharmaceutical 9,10-dihydro ergot alkaloid containing compositions
IT1292126B1 (it) Esteri cerosi arricchiti in acidi grassi omega-3 insaturi,loro preparazione ed uso
TH14737A (th) สารผสมทางเภสัชศาสตร์ที่คงตัวของอนุพันธ์ฟิวแมจิลลอล
IT1232963B (it) Composizioni farmaceutiche topiche contenenti antiistaminici h2
IT1226144B (it) Di estere fosforico dell'acido ursodeossicolico e suoi derivati, processo per la loro preparazione e composizioni terapeutiche che li contengono come principi attivi.
CA2309033A1 (en) Lacrimal gland specific emulsions for topical application to ocular tissue
CA2572498A1 (en) Biphasic capsule formulation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN